Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

MXCT

MaxCyte Inc

Dec 10 • 04:00PM ET

4.19

Dollar change +0.02
Percentage change 0.48	%

Healthcare • Medical Devices • USA • NASD

Peers: NTLA CRSP EDIT SGMO BEAM CRBU CDXS ABCL ALLO

| Held by: IWM VTI VXF IWN IBB VTWO VHT IWC DFAS AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.34	Insider Own	7.72%	Shs Outstand	105.30M	Perf Week	17.04%
Market Cap	441.97M	Forward P/E	-	EPS next Y	-0.38	Insider Trans	-3.19%	Shs Float	97.34M	Perf Month	23.78%
Income	-35.73M	PEG	-	EPS next Q	-0.12	Inst Own	65.13%	Short Float	3.14%	Perf Quarter	7.16%
Sales	45.60M	P/S	9.69	EPS this Y	-11.97%	Inst Trans	-0.33%	Short Ratio	6.05	Perf Half Y	-10.47%
Book/sh	2.03	P/B	2.07	EPS next Y	9.07%	ROA	-13.87%	Short Interest	3.06M	Perf Year	-13.61%
Cash/sh	1.46	P/C	2.87	EPS next 5Y	-	ROE	-16.00%	52W Range	3.16 - 5.55	Perf YTD	-10.85%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.20%	ROI	-15.49%	52W High	-24.44%	Beta	-
Dividend TTM	-	Quick Ratio	9.22	Sales past 5Y	20.83%	Gross Margin	76.80%	52W Low	32.39%	ATR (14)	0.23
Dividend Ex-Date	-	Current Ratio	9.81	EPS Y/Y TTM	5.99%	Oper. Margin	-101.56%	RSI (14)	67.36	Volatility	6.82% 6.36%
Employees	143	Debt/Eq	0.09	Sales Y/Y TTM	19.85%	Profit Margin	-78.36%	Recom	1.00	Target Price	8.86
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	-1.10%	Payout	-	Rel Volume	1.96	Prev Close	4.17
Sales Surprise	9.47%	EPS Surprise	8.33%	Sales Q/Q	1.99%	Earnings	Nov 06 AMC	Avg Volume	505.57K	Price	4.19
SMA20	17.24%	SMA50	14.50%	SMA200	1.85%	Trades		Volume	971,790	Change	0.48%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-23	Initiated	Craig Hallum	Buy	$7
Oct-15-21	Resumed	Cowen	Outperform
Aug-24-21	Initiated	William Blair	Outperform
Aug-24-21	Initiated	Wedbush	Outperform	$36
Aug-24-21	Initiated	Stifel	Buy	$18
Aug-24-21	Initiated	Stephens	Overweight	$19
Aug-24-21	Initiated	Cowen	Outperform
Aug-24-21	Initiated	BTIG Research	Buy	$22

Dec-09-24 02:00AM	MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance (GlobeNewswire) +15.83%
Nov-13-24 08:05AM	MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics (GlobeNewswire)
Nov-07-24 02:00PM	MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ... (GuruFocus.com) -10.82%
Nov-06-24 05:55PM	MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance (GlobeNewswire)
08:05AM	Loading…
Oct-31-24 08:05AM	MaxCyte to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Oct-16-24 12:00PM	MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Oct-15-24 08:05AM	MaxCyte Appoints Cynthia Collins to its Board of Directors (GlobeNewswire)
Oct-11-24 08:05AM	MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-10-24 08:05AM	MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer (GlobeNewswire)
Oct-09-24 05:08PM	MaxCyte Inc (MXCT) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Core Challenges (GuruFocus.com) -5.41%
Sep-17-24 03:32AM	MaxCyte and Kamau Therapeutics sign platform license agreement (Pharmaceutical Technology)
Sep-16-24 02:00AM	MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases (GlobeNewswire)
Sep-05-24 04:05PM	MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference (GlobeNewswire)
Aug-06-24 05:50PM	MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -8.31%
04:05PM	Loading…
04:05PM	MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance (GlobeNewswire)
Jul-17-24 08:50AM	MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jul-09-24 04:05PM	MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jun-13-24 09:55AM	Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect? (Zacks)
08:50AM	Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why (Zacks)
Jun-11-24 01:30AM	Insider Buying: President and CEO Maher Masoud Acquires 100,000 Shares of MaxCyte Inc (MXCT) (GuruFocus.com) -5.65%
May-29-24 08:05AM	MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference (GlobeNewswire)
May-22-24 08:05AM	MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development (GlobeNewswire)
May-12-24 08:19AM	MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 02:39PM	MaxCyte Shares Rise Sharply After Q1 Results Beat (MT Newswires) +18.07%
06:35AM	Q1 2024 MaxCyte Inc Earnings Call (Thomson Reuters StreetEvents)
03:58AM	MaxCyte Inc (MXCT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ... (GuruFocus.com)
May-07-24 08:58PM	MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:45PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance (GlobeNewswire)
08:05AM	Loading…
Apr-10-24 08:05AM	MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-02-24 08:05AM	MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) (GlobeNewswire)
Mar-14-24 08:15AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 08:17AM	11 Oversold Healthcare Stocks To Buy Right Now (Insider Monkey)
Mar-12-24 05:31PM	MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance (GlobeNewswire)
Mar-04-24 04:05PM	MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results (GlobeNewswire) -12.21%
Feb-09-24 08:05AM	MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-30-24 08:05AM	MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugens Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers (GlobeNewswire)
Jan-23-24 08:05AM	MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs (GlobeNewswire)
Jan-08-24 04:05PM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +13.73%
Jan-03-24 08:05AM	MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline (GlobeNewswire) -11.60%
Jan-02-24 02:00AM	MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director (GlobeNewswire) +6.38%
Dec-19-23 11:21AM	Hedge Funds Say These Penny Stocks Are Poised to Explode (Insider Monkey) +9.01%
Dec-11-23 04:05PM	MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023 (GlobeNewswire)
Dec-07-23 11:05AM	Insider Sell Alert: President and CEO Douglas Doerfler Sells 124,450 Shares of MaxCyte Inc (MXCT) (GuruFocus.com)
Dec-02-23 09:04AM	Insider Sell Alert: President and CEO Douglas Doerfler Sells 25,550 Shares of MaxCyte Inc (MXCT) (GuruFocus.com)
Nov-16-23 08:05AM	MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member (GlobeNewswire)
Nov-09-23 12:57PM	MaxCyte, Inc. (NASDAQ:MXCT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 04:05PM	MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance (GlobeNewswire)
Nov-06-23 04:05PM	MaxCyte to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Oct-05-23 12:59PM	Why Shares of MaxCyte Are Plummeting on Thursday (Motley Fool) -20.64%
08:47AM	Why Is MaxCyte (MXCT) Stock Down 21% Today? (InvestorPlace)
Oct-04-23 04:05PM	MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance (GlobeNewswire) +9.00%
Sep-06-23 08:05AM	MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing (GlobeNewswire)
Sep-05-23 08:05AM	MaxCyte to Participate in Baird Global Healthcare Conference (GlobeNewswire)
Aug-09-23 04:05PM	MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance (GlobeNewswire) -10.44%
Aug-01-23 08:05AM	MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients (GlobeNewswire)
Jul-13-23 08:05AM	MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023 (GlobeNewswire)
Jul-10-23 08:05AM	MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies (GlobeNewswire) +7.78%
Jul-08-23 04:54AM	MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 77% of the company (Simply Wall St.)
Jul-06-23 08:05AM	MaxCyte Signs Strategic Platform License with Lyell Immunopharma (GlobeNewswire)
Jun-01-23 04:05PM	MaxCyte to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.56%
May-30-23 08:18AM	Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth (Simply Wall St.)
May-14-23 03:11AM	Earnings Working Against MaxCyte, Inc.'s (LON:MXCT) Share Price Following 28% Dive (Simply Wall St.)
May-10-23 05:25PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -19.78%
04:05PM	MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance (GlobeNewswire)
May-04-23 08:05AM	MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform (GlobeNewswire)
Apr-28-23 05:03AM	MaxCyte, Inc. (LON:MXCT) insider upped their holding by 400% earlier this year (Simply Wall St.)
Apr-27-23 06:36PM	7 Small-Cap Biotech Stocks with Massive Potential (InvestorPlace)
Apr-12-23 04:05PM	MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023 (GlobeNewswire)
Apr-06-23 09:30AM	The three-year returns have been strong for MaxCyte (LON:MXCT) shareholders despite underlying losses increasing (Simply Wall St.)
Mar-27-23 04:05PM	MaxCyte Appoints Douglas Swirsky as Chief Financial Officer (GlobeNewswire)
Mar-18-23 02:06AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-17-23 01:33AM	MaxCyte Full Year 2022 Earnings: US$0.23 loss per share (vs US$0.21 loss in FY 2021) (Simply Wall St.)
Mar-15-23 04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) +6.43%
Mar-08-23 08:00AM	MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology (GlobeNewswire)
Mar-06-23 04:05PM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance (PR Newswire) -7.55%
Feb-22-23 06:37PM	7 Must-Buy Penny Stocks to Add to Your Portfolio in 2023 (InvestorPlace)
Feb-01-23 04:05PM	MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-29-23 03:03AM	A fantastic week for MaxCyte, Inc.'s (LON:MXCT) 70% institutional owners, one-year returns continue to impress (Simply Wall St.)
Jan-03-23 04:05PM	MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs (PR Newswire) -6.23%
Dec-21-22 09:35AM	MaxCyte, Inc. (MXCT) Loses 18.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Dec-19-22 12:55PM	7 Hot Stocks to Book Profits In Before 2023 (InvestorPlace)
Dec-16-22 06:42AM	MaxCyte (LON:MXCT) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Dec-08-22 12:00PM	MaxCyte, Inc. (MXCT) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Dec-05-22 02:00AM	MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases (GlobeNewswire) -10.69%
Nov-19-22 03:18AM	Insiders who bought in the last 12 months lose an additional US$55k as MaxCyte, Inc. (LON:MXCT) drops to UK£566m (Simply Wall St.)
Nov-09-22 06:35PM	MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -9.36% +15.74%
05:35PM	MaxCyte Reports Third Quarter 2022 Financial Results (PR Newswire)
Nov-02-22 08:05AM	MaxCyte to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-23-22 07:29PM	Should You Invest in MaxCyte (MXCT)? (Insider Monkey)
Oct-20-22 10:16AM	MaxCyte (LON:MXCT) shareholders have earned a 65% CAGR over the last three years (Simply Wall St.)
Oct-18-22 11:38AM	Should You Invest in MaxCyte (MXCT)? (Insider Monkey)
Oct-12-22 08:00AM	MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022 (GlobeNewswire)
Sep-28-22 12:39PM	MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders (Benzinga) +7.57%
08:05AM	MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program (GlobeNewswire)
Sep-21-22 09:32AM	Montgomery County biotech MaxCyte unveils new HQ to expand headcount, manufacturing (American City Business Journals)
08:23AM	MaxCyte, Inc. (MXCT) Moves 9.3% Higher: Will This Strength Last? (Zacks)
08:05AM	MaxCyte Debuts New State-of-the-Art Headquarters in Marylands I-270 Biotech Corridor (GlobeNewswire)

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Johnston John Joseph	Director	Dec 09 '24	Option Exercise	2.35	2,495	5,863	144,445	Dec 10 04:30 PM
Johnston John Joseph	Director	Dec 06 '24	Option Exercise	2.93	505	1,478	142,455	Dec 10 04:30 PM
Johnston John Joseph	Director	Dec 09 '24	Sale	3.79	2,495	9,459	141,950	Dec 10 04:30 PM
Johnston John Joseph	Director	Dec 06 '24	Sale	3.70	505	1,869	141,950	Dec 10 04:30 PM
Erck Stanley C	Director	Nov 01 '24	Option Exercise	0.04	47,689	1,908	316,807	Nov 05 04:25 PM
Erck Stanley C	Director	Nov 01 '24	Sale	3.72	47,689	177,403	269,118	Nov 05 04:25 PM
Johnston John Joseph	Director	Oct 28 '24	Option Exercise	2.93	3,000	8,778	144,950	Oct 30 04:15 PM
Johnston John Joseph	Director	Oct 28 '24	Sale	3.72	3,000	11,166	141,950	Oct 30 04:15 PM
Erck Stanley C	Director	Oct 01 '24	Option Exercise	0.04	26,082	1,043	295,200	Oct 02 05:03 PM
Erck Stanley C	Director	Oct 02 '24	Option Exercise	0.04	21,607	864	290,725	Oct 02 05:03 PM
Erck Stanley C	Director	Oct 01 '24	Sale	3.78	26,082	98,590	269,118	Oct 02 05:03 PM
Erck Stanley C	Director	Oct 02 '24	Sale	3.71	21,607	80,162	269,118	Oct 02 05:03 PM
Johnston John Joseph	Director	Sep 26 '24	Option Exercise	2.93	3,000	8,778	144,950	Sep 30 04:15 PM
Johnston John Joseph	Director	Sep 26 '24	Sale	3.82	3,000	11,460	141,950	Sep 30 04:15 PM
Johnston John Joseph	Affiliate	Sep 26 '24	Proposed Sale	3.81	9,000	34,290		Sep 26 04:11 PM
Erck Stanley C	Director	Sep 04 '24	Option Exercise	0.04	29,767	1,191	298,885	Sep 05 05:10 PM
Erck Stanley C	Director	Sep 03 '24	Option Exercise	0.04	17,922	717	287,040	Sep 05 05:10 PM
Erck Stanley C	Director	Sep 04 '24	Sale	3.97	29,767	118,175	269,118	Sep 05 05:10 PM
Erck Stanley C	Director	Sep 03 '24	Sale	4.10	17,922	73,480	269,118	Sep 05 05:10 PM
Erck Stanley C	Officer	Sep 03 '24	Proposed Sale	4.32	143,067	618,049		Sep 03 04:36 PM
Johnston John Joseph	Director	Aug 26 '24	Option Exercise	2.93	3,000	8,778	144,950	Aug 28 04:30 PM
Johnston John Joseph	Director	Aug 26 '24	Sale	4.28	3,000	12,840	141,950	Aug 28 04:30 PM
Ross Thomas M.	EVP, GLOBAL SALES	Aug 02 '24	Option Exercise	1.64	17,857	29,303	42,857	Aug 05 06:57 PM
Ross Thomas M.	EVP, GLOBAL SALES	Aug 01 '24	Option Exercise	1.64	15,476	25,396	40,476	Aug 05 06:57 PM
Ross Thomas M.	EVP, GLOBAL SALES	Aug 02 '24	Sale	4.36	17,857	77,874	25,000	Aug 05 06:57 PM
Ross Thomas M.	EVP, GLOBAL SALES	Aug 01 '24	Sale	4.54	15,476	70,261	25,000	Aug 05 06:57 PM
Johnston John Joseph	Director	Jul 26 '24	Option Exercise	2.93	3,000	8,778	144,950	Jul 30 04:39 PM
Johnston John Joseph	Director	Jul 26 '24	Sale	4.75	3,000	14,238	141,950	Jul 30 04:39 PM
Ross Thomas M.	EVP, GLOBAL SALES	Jul 08 '24	Option Exercise	1.64	19,802	32,495	44,802	Jul 10 04:15 PM
Ross Thomas M.	EVP, GLOBAL SALES	Jul 09 '24	Option Exercise	1.64	13,531	22,204	38,531	Jul 10 04:15 PM
Ross Thomas M.	EVP, GLOBAL SALES	Jul 08 '24	Sale	4.03	19,802	79,782	25,000	Jul 10 04:15 PM
Ross Thomas M.	EVP, GLOBAL SALES	Jul 09 '24	Sale	4.03	13,531	54,584	25,000	Jul 10 04:15 PM
Johnston John Joseph	Director	Jun 27 '24	Option Exercise	2.28	10,000	22,778	151,950	Jul 01 05:18 PM
Johnston John Joseph	Director	Jun 27 '24	Sale	3.99	10,000	39,900	141,950	Jul 01 05:18 PM
Ross Thomas M.	EVP, GLOBAL SALES	Jun 20 '24	Option Exercise	1.64	33,333	54,699	58,333	Jun 24 04:17 PM
Ross Thomas M.	EVP, GLOBAL SALES	Jun 20 '24	Sale	4.09	33,333	136,465	25,000	Jun 24 04:17 PM
Masoud Maher	President and CEO	Jun 10 '24	Buy	4.90	70,443	345,241	100,000	Jun 10 05:55 PM
Masoud Maher	President and CEO	Jun 07 '24	Buy	4.87	29,557	143,824	29,557	Jun 10 05:55 PM
Johnston John Joseph	Director	Mar 26 '24	Option Exercise	2.14	5,000	10,710	125,583	Mar 28 04:31 PM
Johnston John Joseph	Director	Mar 26 '24	Sale	4.41	5,000	22,025	120,583	Mar 28 04:31 PM
Johnston John Joseph	Director	Jan 26 '24	Option Exercise	2.14	5,000	10,710	125,583	Jan 30 04:30 PM
Johnston John Joseph	Director	Jan 26 '24	Sale	5.12	5,000	25,585	120,583	Jan 30 04:30 PM
Johnston John Joseph	Director	Dec 26 '23	Option Exercise	2.14	5,000	10,710	125,583	Dec 28 04:30 PM
Johnston John Joseph	Director	Dec 26 '23	Sale	4.53	5,000	22,650	120,583	Dec 28 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MXCT

MaxCyte Inc

Upgrade your FINVIZ experience